Marshall Wace, LLP Atreca, Inc. Transaction History

Marshall Wace, LLP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.56 - $3.25 $229,195 - $477,490	-146,920 Reduced 84.55%	26,839 $48,000
Q1 2022 May 16, 2022	BUY	$1.61 - $5.2 $224,263 - $724,328	139,294 Added 404.16%	173,759 $551,000
Q2 2021 Aug 13, 2021	BUY	$7.82 - $13.8 $269,516 - $475,617	34,465 New	34,465 $294,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.